Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Rhea-AI Summary

Jin Medical International (NASDAQ: ZJYL) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. The Company restored compliance after its Class A ordinary shares maintained a closing bid of at least $1.00 per share for more than ten consecutive business days. The Company said it will continue focusing on core operations and ongoing strategic initiatives.

Positive

• Regained Nasdaq minimum bid-price compliance after >10 consecutive business days
• Class A shares closed at or above $1.00 for the required compliance period

Negative

• None.

News Market Reaction – ZJYL

+1.52%

5 alerts

+1.52% Session close to close

+15.0% Peak in 27 hr 5 min

$19.17M Market Cap

0.7x Rel. Volume

In the Apr 7 session, ZJYL gained 1.52%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.0% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms that Jin Medical regained compliance with Nasdaq’s $1.00 minimum bid pric...

Analysis

This announcement confirms that Jin Medical regained compliance with Nasdaq’s $1.00 minimum bid price after more than 10 consecutive qualifying sessions, reducing near-term delisting risk. It follows earlier capital-structure steps, including a 1-for-20 share combination aimed at supporting listing standards. Shares still trade well below the 200-day MA and 89.95% under the 52-week high, while an unused shelf of up to $300 million and capital-allocation decisions remain important variables to monitor.

Key Figures

Minimum bid price: $1.00 per share Compliance streak: More than 10 business days Current price: $1.98 +1 more

4 metrics

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) compliance threshold

Compliance streak More than 10 business days Closing bid at or above $1.00

Current price $1.98 Pre-news market context price

Price change 24h 7.03% Move prior to compliance headline

Historical Context

5 past events · Latest: Mar 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 11	Share combination, compliance	Negative	-18.3%	1-for-20 share combination and recapitalization to support Nasdaq compliance.
Feb 05	CEO fireside chat	Positive	+1.6%	CEO outlined strategic priorities, reverse split plan, and manufacturing scale-up.
Jan 26	Upcoming fireside chat	Positive	+4.8%	Announcement of management fireside chat on strategy and long-term growth.
Jan 22	Chuzhou facility update	Positive	+3.2%	Chuzhou plant cleared for Class I devices with full capacity targeted by April 2026.
Jan 21	Planned fireside chat	Positive	-4.1%	Planned chat on strategic priorities and capital structure from a stated strong liquidity base.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mostly produced price moves aligned with the underlying sentiment, with only one notable divergence on a capital-structure update.

Recent Company History

Over the last few months, Jin Medical has focused on Nasdaq compliance and capital structure while scaling manufacturing. A 1-for-20 share combination and dual-class structure were implemented to support continued listing, which previously drew a -18.34% reaction. Multiple fireside chats outlined strategic priorities and capital plans, with generally positive price responses. Operationally, the new Chuzhou facility targets 200,000 units of annual capacity by end of April 2026. Today’s confirmation of bid-price compliance fits this broader effort to stabilize listing status alongside expansion.

Key Terms

minimum bid price requirement, class a ordinary shares

2 terms

minimum bid price requirement regulatory

"Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement."

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

class a ordinary shares financial

"after its Class A ordinary shares maintained a closing bid price of at least $1.00"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has received written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.

The Company regained compliance after its Class A ordinary shares maintained a closing bid price of at least $1.00 per share for more than ten (10) consecutive business days.

The Company will continue to focus on its core business operations and ongoing strategic initiatives.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
ir@jinmed.com

View original content:https://www.prnewswire.com/news-releases/jin-medical-international-ltd-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement-302735210.html

SOURCE Jin Medical International Ltd.

FAQ

What did Jin Medical (ZJYL) announce on April 7, 2026 about Nasdaq compliance?

Jin Medical confirmed it has regained Nasdaq minimum bid-price compliance. According to the company, the Class A ordinary shares maintained a closing bid of at least $1.00 per share for more than ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2).

How long did ZJYL shares need to trade at $1.00 to regain Nasdaq compliance?

Shares needed to close at or above $1.00 for more than ten consecutive business days. According to the company, that closing-price streak is the specific Nasdaq requirement that restored compliance under Rule 5550(a)(2).

What does regaining Nasdaq compliance mean for ZJYL shareholders now?

Regaining compliance means ZJYL avoids immediate delisting risk tied to minimum bid price. According to the company, the restored status lets management focus on operations and strategic initiatives rather than addressing a Nasdaq deficiency.

Will Jin Medical (ZJYL) face further Nasdaq review after regaining compliance?

Nasdaq may continue monitoring the listing standard going forward. According to the company, compliance was regained by meeting the required closing-price condition, but ongoing market-priced compliance remains subject to Nasdaq monitoring.

Where can investors verify Jin Medical's (ZJYL) Nasdaq compliance status after April 7, 2026?

Investors can confirm listing status via Nasdaq's public Listing Qualifications notices or the company's disclosures. According to the company, Nasdaq's Listing Qualifications Department provided written confirmation of regained compliance on April 7, 2026.

Does regaining Nasdaq compliance change Jin Medical's (ZJYL) business operations or strategy?

The company said it will continue focusing on core operations and strategic initiatives. According to the company, regaining compliance allows management to maintain attention on business execution rather than addressing a bid-price deficiency.